Oculis to Present Phase 2 Biomarker Data on October 22
The company will share new trial results for its drug candidate Privosegtor at an upcoming international medical meeting.
Updated on Oct. 20, 2026 in Stroke
Live Poll
Do you trust pharmaceutical companies to prioritize finding treatments for rare conditions?
Oculis Holding AG is scheduled to present Phase 2 biomarker data from its ACUITY trial of Privosegtor on October 22, 2026. The presentation will occur during a late-breaking session at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto.
Why it matters
The trial data offers insight into neuroprotection and acute central nervous system injury cascades. These findings are significant for the development of potential treatments for optic neuritis and acute multiple sclerosis relapses.
The ACUITY trial evaluates plasma biomarkers, specifically neurofilament light chain and glial fibrillary acidic protein, as indicators of neuroaxonal injury. Optic neuritis currently impacts roughly 30,000 people annually in the United States.
The players
Oculis Holding AG
This Zug-based biopharmaceutical company focuses on developing innovative therapies for ophthalmic and central nervous system diseases.
Céline Louapre
She serves as the principal investigator for the Phase 2 ACUITY trial examining the efficacy of Privosegtor.
The details
The research focuses on characterizing the role of plasma biomarkers in measuring neuroinflammation. Privosegtor has already secured Breakthrough Therapy and Priority Medicines designations from the FDA and EMA, respectively, and is also classified as an Orphan Drug.
Timeline
The 10th Joint ACTRIMS-ECTRIMS Meeting runs from October 21-23, 2026.
The presentation of ACUITY trial biomarker data occurs on October 22, 2026.
Oculis plans to host an R&D Day on December 8, 2026.
The Big Picture
The presentation of the ACUITY data follows the established clinical development framework set by the PIONEER program.
Patients dealing with optic neuritis or acute multiple sclerosis relapses may see new treatment options emerge as the drug moves through clinical trials. The research seeks to improve clinical monitoring for these conditions using plasma biomarkers.
The takeaway
The use of neurofilament light chain and glial fibrillary acidic protein as biomarkers represents a shift toward more precise monitoring of central nervous system injury. Tracking these indicators is expected to assist in the development of more effective neuroprotective therapies.
What happens next
Oculis is scheduled to hold an R&D Day on December 8, 2026, which may provide further updates on its drug pipeline.
Further reading
Learn more about the latest research and developments in the field of Stroke.
Live Poll
Do you trust pharmaceutical companies to prioritize finding treatments for rare conditions?
